LONDON MARKET CLOSE: Blue chips fall but FTSE 250 extends winning run
(Alliance News) - The FTSE 100 fell on Thursday despite well-received earnings, but mid-caps extended their recent gains, lifted by advances by WPP and easyJet. Read More
| Price | 11,682.00p on 12-08-2026 at 12:12:20 |
|---|---|
| Change | -162.00p -1.37% |
| Buy | 11,684.00p |
| Sell | 11,682.00p |
| Last Trade: | Unknown 0.00 at 11,684.00p |
| Day's Volume: | 611,450 |
| Last Close: | 11,844.00p |
| Open: | 11,786.00p |
| ISIN: | GB0009895292 |
| Day's Range | 11,674.00p - 11,796.00p |
| 52wk Range: | 10,784.00p - 15,730.00p |
| Market Capitalisation: | £181.17b |
| VWAP: | 11,719.28199p |
| Shares in Issue: | 1.55b |
Astrazeneca (AZN) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 0 | 11,684.00p | SI Trade |
13:12:20 - 12-Aug-26 |
| Sell* | 82 | 11,682.00p | Automatic Execution |
13:12:07 - 12-Aug-26 |
| Sell* | 4 | 11,682.00p | Automatic Execution |
13:12:07 - 12-Aug-26 |
| Sell* | 20 | 11,682.00p | Automatic Execution |
13:12:07 - 12-Aug-26 |
| Sell* | 9 | 11,682.00p | Automatic Execution |
13:12:07 - 12-Aug-26 |
| Sell* | 20 | 11,682.00p | Automatic Execution |
13:12:07 - 12-Aug-26 |
| Buy* | 1,500 | 11,683.651p | Ordinary |
13:11:55 - 12-Aug-26 |
| Buy* | 7 | 11,684.00p | SI Trade |
13:11:50 - 12-Aug-26 |
| Unknown* | 0 | 11,688.00p | SI Trade |
13:11:45 - 12-Aug-26 |
| Sell* | 27 | 11,686.00p | Automatic Execution |
13:11:45 - 12-Aug-26 |
Astrazeneca (AZN) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 3rd Aug 2026 3:05 pm | RNS | Admission of Further Securities to Trading |
| 3rd Aug 2026 3:00 pm | RNS | Total Voting Rights |
| 31st Jul 2026 7:30 am | RNS | Datroway approved in EU for TNBC |
| 27th Jul 2026 7:10 am | RNS | Update on Ultomiris Phase III trial in HSCT-TMA |
| 27th Jul 2026 7:05 am | RNS | Sone-Ve improved survival in gastric cancers |
| 27th Jul 2026 7:00 am | RNS | Half-year Financial Report |
| 23rd Jul 2026 7:00 am | RNS | Etcamah approved in the EU for ER+ breast cancer |
| 14th Jul 2026 7:00 am | RNS | AstraZeneca licenses novel EGFR inhibitor |
| 9th Jul 2026 7:00 am | RNS | Update on CARDIO-TTRansform Phase III trial |
| 1st Jul 2026 3:05 pm | RNS | Admission of Further Securities to Trading |